A Comparison of Three Extrusion Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Comparison of Three Extrusion Systems
The authors conducted an experiment to determine the type of extrusion that provides the best productivity and pellet quality. This article contains online bonus material.


Pharmaceutical Technology
Volume 35, Issue 1

16. D. Sonaglio et al., Pharmazie 52 (2), 129–134 (1997).

17. D. Djuric et al., Eur. J. Pharm. Biopharm. 71 (1), 155–160 (2009).

18. A. Debunne, C. Vervaet, and J.P. Remon, Eur. J. Pharm. Biopharm. 54 (3), 343–348 (2002).

19. A. Dukić et al., Eur. J. Pharm. Biopharm. 66 (1), 83–94 (2007).

20. H. Kanbe et al., Int. J. Pharm. 337 (1–2), 56–62 (2007).

21. A. Dukić-Ott et al., Eur. J. Pharm. Biopharm. 70 (1), 302–312 (2008).

22. K.E. Fielden, J.M. Newton, and R.C. Rowe, Int. J. Pharm. 97 (1–3), 79–92 (1993).

23. E. Jerwanska et al., Int. J. Pharm. 121 (1), 65–71 (1995).

24. J.J. Sousa et al., Int. J. Pharm. 144 (2), 159–169 (1996).

25. L. Hellén et al., J. Pharm. Tech. Int. 4 (9), 50–60 (1992).

26. G.A. Hileman et al., Int. J. Pharm. 100 (1–3), 71–79 (1993).

27. C.C. Ku et al., Drug Dev. Ind. Pharm. 19 (13), 1505–1519 (1993).

28. B. Bataille, K. Ligarski, and M. Jacob, Pharm. Acta Helv. 65 (12), 334–337 (1990).

29. D. Sonaglio et al., Int. J. Pharm. 115 (1), 53–60 (1995).

30. K.A. Mehta et al., J. Control. Release 63 (1–2), 201–211 (2000).

31. S. Galland et al., Chem. Eng. Res. Des. 81 (9), 1237–1242 (2003).

32. S. Galland et al., Powder Technol. 157 (1–3), 156–162 (2005).

33. P. Kleinebudde and H. Lindner, Int. J. Pharm. 94 (1–3), 49–58 (1993).

34. D. Lutchman, C.M. Dangor, and D. Perumal, J. Microencapsul. 22 (6), 643–659 (2005).

35. C. Vervaet et al., Int. J. Pharm. 107 (1), 29–39 (1994).

36. C. Vervaet and J.P. Remon, Int. J. Pharm. 133 (1–2), 29–37 (1996).

37. R. Dietrich and R. Brausse, Pharm. Ind. 50 (10), 1179–1186 (1988).

38. A.M. Juppo et al., Eur. J. Pharm. Biopharm. 44 (2) 205–214 (1997).

39. P.J. Harrison, J.M. Newton, and R.C. Rowe, J. Pharm. Pharmacol. 37 (10), 686–691 (1985).

40. J.F. Pinto, G. Buckton, and J.M. Newton, Int. J. Pharm. 83 (1–3), 187–196 (1992).

41. L. Baert and G.R.B. Down, Int. J. Pharm. 107 (3), 219–222 (1994).

42. C. Lustig-Gustafsson et al., Eur. J. Pharm. Sci. 8 (2), 147–152 (1999).

43. G. Tomer, F.Podczeck, and J.M. Newton, Int. J. Pharm. 217 (1–2), 237–248 (2001).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here